c-MET (H1094L)

MET · Variant type: point · HGVS: p.H1094L

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Tepotinib	98.0%	2.0%	99.75
2	Capmatinib	96.6%	3.4%	99.75
3	Deucravacitinib	86.9%	13.1%	98.99
4	Tivozanib	60.9%	39.1%	92.42
5	Gilteritinib	59.5%	40.5%	88.97
6	Erdafitinib	56.2%	43.8%	95.71
7	Pacritinib	35.1%	64.9%	88.64
8	Selpercatinib	33.6%	66.4%	96.72
9	Defactinib	31.1%	68.9%	92.68
10	Sunitinib	30.0%	70.0%	91.73
11	Repotrectinib	20.4%	79.6%	84.21
12	Ripretinib	18.5%	81.5%	92.95
13	Neratinib	16.4%	83.6%	93.18
14	Canertinib	14.8%	85.2%	96.49
15	Pexidartinib	14.1%	85.9%	99.49
16	Fedratinib	13.9%	86.1%	96.21
17	Avapritinib	13.6%	86.4%	97.73
18	Pirtobrutinib	9.3%	90.7%	99.49
19	Abrocitinib	8.6%	91.4%	99.50
20	Upadacitinib	7.3%	92.7%	97.98
21	Paxalisib	6.6%	93.4%	99.75
22	Infigratinib	6.3%	93.7%	98.24
23	Pemigatinib	6.1%	93.9%	98.23
24	Pralsetinib	5.7%	94.3%	93.43
25	Mitapivat	5.0%	95.0%	100.00

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Tepotinib	98.0%	—	—
Capmatinib	96.6%	—	—
Deucravacitinib	86.9%	—	—
Tivozanib	60.9%	—	—
Gilteritinib	59.5%	—	—
Erdafitinib	56.2%	—	—
Pacritinib	35.1%	—	—
Selpercatinib	33.6%	—	—
Defactinib	31.1%	—	—
Sunitinib	30.0%	—	—
Repotrectinib	20.4%	—	—
Ripretinib	18.5%	—	—
Neratinib	16.4%	—	—
Canertinib	14.8%	—	—
Pexidartinib	14.1%	—	—
Fedratinib	13.9%	—	—
Avapritinib	13.6%	—	—
Pirtobrutinib	9.3%	—	—
Abrocitinib	8.6%	—	—
Upadacitinib	7.3%	—	—
Paxalisib	6.6%	—	—
Infigratinib	6.3%	—	—
Pemigatinib	6.1%	—	—
Pralsetinib	5.7%	—	—
Mitapivat	5.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.9ms